A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) ...
Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback